Ceftazidime for injection

This product is a third-generation cephalosporin antibiotic. It has high antibacterial activity against Escherichia coli, Klebsiella pneumoniae and other Enterobacteriaceae, Haemophilus influenzae, Pseudomonas aeruginosa, etc. It also has good antibacterial effects on nitrate-negative bacilli, Alcaligenes, etc. Most beta-lactamases produced by bacteria are highly stable, so it can still have antibacterial activity against multi-drug resistant strains of the vast majority of Gram-negative bacilli mentioned above. Gram-positive cocci such as pneumococci and hemolytic streptococci are highly sensitive to this product, but this product has only moderate activity against staphylococci, while enterococci and methicillin-resistant Staphylococci are often resistant to this product. This product has certain antibacterial activity against anaerobic bacteria such as Peptococcus and Peptostreptococci, but has poor antibacterial effect against Bacteroides fragilis. Its mechanism of action is to bind to penicillin-binding proteins (PBPs) on the bacterial cell membrane, acylate the transpeptidase, inhibit the synthesis of the bacterial septum and cell wall, affect the cross-linking of the cell wall mucopeptide components, inhibit cell division and growth, elongate the bacterial morphology, and finally dissolve and die.

The main ingredient of this product is ceftazidime, and its chemical name is (6R,7R)-7-[[(2-amino-4-thiazolyl)-[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-3-methylpyridinium inner salt pentahydrate.

This product is white or off-white crystalline powder.

It is used for sepsis, lower respiratory tract infection, abdominal and biliary tract infection, complicated urinary tract infection and severe skin and soft tissue infection caused by sensitive Gram-negative bacilli. It is especially suitable for infections in immunocompromised patients caused by multiple drug-resistant Gram-negative bacilli, hospital-acquired infections, and central nervous system infections caused by Gram-negative bacilli or Pseudomonas aeruginosa.

Intravenous injection or intravenous drip. 1 For sepsis, lower respiratory tract infection, biliary tract infection, etc., 4-6g a day, divided into 2-3 intravenous drips or intravenous injections, the course of treatment is 10-14 days; 2 For urinary tract infection and severe skin and soft tissue infection, 2-4g a day, divided into 2 intravenous drips or intravenous injections, the course of treatment is 7-14 days. 3 For certain life-threatening infections, severe Pseudomonas aeruginosa infections and central nervous system infections, the dosage can be increased to 0.15-0.2g/kg a day, divided into 3 intravenous drips or intravenous injections. 4 The common dose for infants and young children is 30-100mg/kg a day, divided into 2-3 intravenous drips.

The adverse reactions of this product are rare and mild. A small number of patients may experience rash, itchy skin, drug fever; nausea, diarrhea, abdominal pain; mild phlebitis at the injection site; occasional transient increase in serum aminotransferase, blood urea nitrogen, and blood creatinine; leukopenia, thrombocytopenia, and eosinophilia, etc.

It is contraindicated in patients who are allergic to cephalosporin antibiotics.

1. This product is contraindicated with the following drugs: amikacin sulfate, gentamicin, kanamycin, tobramycin, neomycin, chlortetracycline hydrochloride, tetracycline hydrochloride, oxytetracycline hydrochloride, colistin sodium methanesulfonate, polymyxin B sulfate, erythromycin gluconate, erythromycin lactobionate, lincomycin, sulfisoxazole, aminophylline, soluble barbiturates, calcium chloride, calcium glucoheptonate, diphenhydramine hydrochloride and other antihistamines, lidocaine, norepinephrine, metaraminol, methylphenidate, succinylcholine, etc. Occasionally, it may also be contraindicated with the following drugs: penicillin, methicillin, hydrocortisone succinate, phenytoin sodium, prochlorperazine, vitamin B group and vitamin C, hydrolyzed protein. 2. The stability in sodium bicarbonate solution is worse than in other solutions. 3. This product cannot be administered in the same container with aminoglycoside antibiotics. Precipitation may occur when mixed with vancomycin. 4 When this product is used in combination with aminoglycoside antibiotics or strong diuretics such as furosemide, renal function must be closely monitored to avoid the occurrence of renal damage.

Keep tightly closed in a cool, dark place.

1.5g (calculated as C22H22N6O7S2)

Shantou Jinshi Sterilize Powder For Injection Co., Ltd.

• Founded in:

  1994-04-29

• Address:

  No. 36, Taishan Road, Shantou City

• Tax NO.:

  914405002798080307

• Registered Funds:

  17 million yuan

• Website:

  Log in to view

• Email:

  Log in to view